Global Biosecurity Worries Grow Amid Lab Boom and Lagging Oversight

The death of a woman near a Russian facility that studies the plague has heightened global concerns about biosecurity, despite the low likelihood of a widespread outbreak. The incident serves as a stark reminder of the potential risks associated with the growing number of high-containment laboratories worldwide and the concurrent struggle to maintain robust oversight.

While the specific circumstances of the Russian case remain difficult to verify, reports suggest the worker may have been infected after a test tube broke. This potential accident underscores a persistent threat: human error in highly controlled environments. Experts note that the anxiety surrounding the event reflects two critical trends: a surge in the construction of bioresearch facilities globally, including in regions with less experience in handling dangerous pathogens, and a lagging international and national framework for regulating and securing these sites.

"We are rolling back any progress we made post-Covid, in ways that are going to have long-term effects on our ability to respond to any kind of outbreak," said Gregory Koblentz, who studies global biosecurity at George Mason University and co-founded the Global BioLabs project. He noted that the world's preparedness for outbreaks, whether natural or accidental, has diminished in recent years due to self-inflicted issues.

The Rise of High-Level Biolabs

Following the COVID-19 pandemic, there has been a significant increase in the construction of Biosafety Level 4 (BSL-4) laboratories, which are designed to handle the most dangerous pathogens. Global BioLabs reported that in 2021, 59 BSL-4 labs were operational, under construction, or in planning stages worldwide. By 2023, this number increased by 10 more facilities. This acceleration echoes previous buildups after events like the post-9/11 anthrax scares and the early 2000s SARS outbreak.

One driver for this expansion is a lesson learned from the COVID-19 pandemic: developing nations recognized their dependence on wealthier countries during crises. Consequently, many are building domestic capacity to identify and handle dangerous biological materials. India, for example, is planning four new BSL-4 facilities. At least five other countries, including Brazil, Kazakhstan, Saudi Arabia, Singapore, and Spain, have opened or begun constructing their first BSL-4 labs. This expansion into new regions raises concerns about the availability of sufficient institutional experience, governmental stability, and robust oversight systems.

"The more facilities that are working on this raises concerns about whether all this work is necessary," Koblentz stated. "And do they have the appropriate biosafety and biosecurity management systems in place?"

Adding to these concerns, approximately 75 percent of existing operational BSL-4 labs globally are situated in urban centers, with a significant population living within 2.5 miles, which could amplify the impact of any accidental release.

Oversight Challenges

Despite the proliferation of these advanced facilities, national and international standards for their governance and research remain insufficient. There is no global body responsible for inspecting or regulating these sites. The International Experts Group of Biosafety and Biosecurity Regulators, a key voluntary organization, has become defunct. National legislation is also inconsistent, with only one of the 27 countries possessing a BSL-4 lab having comprehensive laws for regulating "dual-use" gain-of-function research, which involves modifying pathogens to study their transmissibility or virulence.

Efforts to strengthen international biosecurity, such as provisions in the World Health Organization's pandemic treaty, have been diluted, and the treaty itself remains unfinalized. Furthermore, the United States' withdrawal from the WHO and cuts to federal agencies responsible for biosecurity oversight have hindered global cooperation in pandemic preparedness.

The Need for Transparency and Safety

While the study of dangerous pathogens is crucial for developing countermeasures and understanding potential threats, the risks involved necessitate a more transparent approach. Scientists engage in this work to prepare for future pandemics, aiming to develop faster therapeutics and vaccines. However, public perception can be swayed by the dual nature of this research – potentially life-saving versus inherently dangerous.

"The real question is: ‘What are the risks and what are the benefits?’" noted Beth Cameron, senior adviser to the Brown Pandemic Center. "We need to have a more rational conversation about what we’re actually talking about."

Implementing new safety protocols, such as those from the International Organization for Standardization, and developing strong national oversight standards are critical steps. Governments must prioritize the mundane but essential work of inspection and maintenance alongside the construction of state-of-the-art facilities.

Koblentz suggested that an international auditing mechanism, analogous to the International Atomic Energy Agency for nuclear safety, would be beneficial. This would foster more open discussions about the necessity and conduct of research at high-security labs.

Reasserting global health leadership by the U.S., including rejoining multinational groups like the WHO and restoring funding for scientific agencies, is also vital for enhancing worldwide biosecurity. The current trajectory suggests that global biosecurity is being undermined by policy decisions, increasing vulnerability to both accidental and deliberate threats.